We are #TeamFormycon! Formycon currently employs more than 240 committed employees from over 33 nations, of which around 60% are women. More than 80% of our colleagues work in research and development.

We recognize the power of diversity and promote it wherever we can. We are committed to a world in which every person – regardless of origin, gender, religion or other characteristics – enjoys the same opportunities and rights. Especially in today’s world, we stand by these values, which are essential for us, our company and our future. All our employees are obliged to familiarize themselves with the General Equal Treatment Act (AGG) through appropriate training when they join the company. This training also includes the Formycon Diversity, Equity and Inclusion policy that prohibits discrimination or harassment of any kind in any of our employment practices, including recruitment, hiring, training, promotion or other matters.

We are proud of our organization, which has grown steadily over the years, and the values we live by,  openness, tolerance, reliability, appreciation and mutual trust. Since 2022, Formycon is actively supporting the LGBTQIA+ community in the company by establishing special communication channels such as “FOR_MY_Queers_Community”, enabling an exchange on the company’s intranet. A separate LGBTQIA+ podcast series on topics such as diversity or international LGBTQIA+ rights not only provides information, but also sensitizes employees and promotes understanding and tolerance.

Formycon takes the issue of  women’s leadership and growth very seriously and strives to provide the work environment to achieve this.  The proportion of women at the second management level (Vice President, Senior Director, Director and Associate Director) was 42.9% as of December 31, 2023. At the highest management level (Board of Directors), the proportion was 25%. Altogether, the proportion of women at Formycon across all management positions is 36.2%.

We are driven by the aim to improve access to modern and effective therapies for patients who have so far been underserved. Our contribution is to develop biosimilars and market them at a lower cost than the original substances. In this way, Formycon not only helps patients worldwide, but also contributes to the sustainable financial relief of healthcare systems.

The safety and quality of our medicines for our patients is a top priority. The development of biosimilars for highly regulated markets requires high standards of safety, quality and efficacy of the drugs. The quality assurance requirements for the production processes related to medicinal products and active ingredients are defined by the European Commission in the Principles and Guidelines of Good Manufacturing Practice (GMP) for medicinal products for human use. Formycon’s laboratories are managed under these guidelines and recurringly inspected and audited by regulatory bodies such as the U.S. Food and Drug Administration (FDA).

The conduct of clinical trials concerning medicinal products for human use is strictly regulated by the Good Clinical Practice (GCP) regulation. The GCP Regulation is valid worldwide and serves to protect patients and the integrity and accuracy of the data and findings generated during such studies. We monitor the compliance with all relevant regulations and standards very closely, not only within our own operations, but also at the sites of our business partners.

We ensure the high quality and safety of our products for patients now and in the future and are working to make them available globally. In addition, we conduct research on and develop more patient-friendly methods to administer our products.

At Formycon, all our products must be safe, effective, and efficient and developed in full compliance with legal requirements.  For the development of biosimilars, it is usually not legally required to test the drug substances on animals. However, in rare cases, we are mandated by law to conduct testing of our products on animals before clinical trials can take place on humans.

Formycon is aware that animal experiments raise a special responsibility. For this reason, we not only comply with all laws and regulations regarding animal testing, but we also enact strict internal rules to ensure that they are treated respectfully and ethically. These rules are based on the 3R principle – to completely avoid animal experiments (Replace), and to minimise the number of animals (Reduce) and their suffering (Refine) in experiments as much as possible.

A careful evaluation takes place before each study, with specific emphasize on the purpose of the study, the effects on the animals and the reasons why no results can be obtained otherwise. The study will only take place if animal experiments are prescribed by mandatory regulation or results cannot be obtained by an alternative method. In addition, all employees who participate must be properly trained and qualified to conduct animal testing. Of course, this also applies to our business partners and their employees.